Skip to main content

Table 3 Patient reported outcomes and quality of life

From: Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET)

  EORTC QLQC30 or PedsQL Hesitancy scale PRO CTCAE Toxicitya
Vaccine dose 1 (− 7) X  X    
D7 (± 1) post dose 1 X    X  
Vaccine dose 2 X     
D7 (± 1) post dose 2 X    X   
3 M post dose 2 X     X 
  1. D day, M month, EORTC QLQ European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, PRO CTCAE Patient Reported Outcomes Common Terminology Criteria for Adverse Events
  2. aMedical record review
Back to article page